文献速递肥胖与代谢综合征

定义疾病还是延迟治疗?对《柳叶刀》肥胖框架的概念与临床评估

Defining disease or delaying care? A conceptual and clinical appraisal of the Lancet obesity framework.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

《柳叶刀糖尿病与内分泌学委员会》提出超越BMI的肥胖共识框架,区分「临床肥胖」与「临床前肥胖」。内分泌学会独立评估其概念一致性、实证支持、操作可行性及对覆盖、公平和临床实施的影响,肯定其概念进步但呼吁在标准化测量、阈值和防止治疗不足等方面完善后再广泛采纳。

要点

  • 框架将肥胖分为「临床肥胖」与「临床前肥胖」,强调脂肪分布而非仅BMI。
  • 验证研究显示「临床前肥胖」者风险已升高,「临床肥胖」者风险更高。
  • 内分泌学会暂未完全背书,因缺乏标准化测量协议和长期数据。

核心结论

  • 委员会框架是概念上的有意义进步,但广泛采纳需实际且公平的实施。

研究设计与样本

  • 内分泌学会对《柳叶刀》肥胖框架进行独立评估,基于现有证据分析概念一致性、实证支持、操作可行性及临床影响。

主要发现

  • 中心性肥胖和脂肪分布比单独BMI更好地预测心脏代谢风险。
  • 验证研究(All of Us;UK Biobank)显示「临床前肥胖」个体风险升高,「临床肥胖」个体风险更高。
  • 缺乏标准化人体测量协议、资源利用增加、皮下与内脏脂肪区分有限及长期数据不足促使内分泌学会暂停完全背书。

关键数值与推荐

  • 「临床肥胖」定义为过剩脂肪堆积加上可归因于脂肪的客观器官/系统功能障碍或功能受限。
  • 「临床前肥胖」定义为过剩脂肪堆积而无上述证据。

临床怎么用

  • 倡导与现有分期系统(EOSS、EASO)协调,明确测量协议,采用年龄、性别和祖先特异性阈值。
  • 整合心理健康和患者报告结局,制定防止意外护理限制的政策。

局限性

  • 缺乏标准化人体测量协议。
  • 资源利用增加。
  • 皮下与内脏脂肪区分有限。
  • 关于肥胖相关疾病缺失的长期影响数据不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Lancet Diabetes & Endocrinology Commission undertook the complex task of addressing limitations in existing definitions and classification of obesity. Its consensus framework moves beyond body mass index (BMI) toward direct or surrogate measures of excess adiposity and distinguishes "clinical obesity" (excess adiposity plus objective organ/system dysfunction or functional limitation attributable to adiposity) from "preclinical obesity" (excess adiposity without such evidence). The Endocrine Society (ES) recognizes the substantial effort and expertise underlying this work and its intent to improve diagnostic precision and therefore provides an independent appraisal of the framework's conceptual coherence, empirical support, operational feasibility, and implications for coverage, equity, and clinical implementation. The shift away from BMI-only screening is supported by evidence that central adiposity and fat distribution better predict cardiometabolic risk than BMI alone. Validation studies (All of Us; UK Biobank) demonstrate elevated risk among individuals classified with "preclinical" obesity and even higher risk among those with "clinical" obesity, underscoring the importance of safeguards against undertreatment in the preclinical state. At the same time, lack of standardized anthropometric measurement protocols, increased resource utilization, limited distinction between subcutaneous and visceral fat depots, and insufficient data regarding the long-term implications of obesity-related disease absence prompted the ES to pause before fully endorsing the Commission's consensus. Accordingly, we outline an evaluation framework addressing available evidence, feasibility, coverage and equity considerations, and clinical impact. We advocate harmonization with established staging systems (EOSS, EASO), explicit measurement protocols, age-, sex-, and ancestry-specific thresholds, integration of mental health and patient-reported outcomes, and policies that prevent unintended care restrictions. The Commission's reframing represents a meaningful conceptual advance; broader adoption will require practical and equitable implementation.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Muniyappa R, Chukir T, Desai D, et al. Defining disease or delaying care? A conceptual and clinical appraisal of the Lancet obesity framework. J Clin Endocrinol Metab. 2026. PMID: 41925581. doi:10.1210/clinem/dgag097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。